Presbyopia - Pipeline Review, H2 2017
Summary
Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H2 2017, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.
Presbyopia is an eye condition in which eye slowly loses the ability to focus quickly on objects that are close. Presbyopia happens in people as they age. Signs and symptoms include headaches, eyestrain, difficulty reading small print and fatigue. Risk factors include anemia, diabetes, cardiovascular disease, hyperopia, multiple sclerosis, myasthenia gravis and eye trauma.
Report Highlights
Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Presbyopia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Presbyopia (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Presbyopia (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Presbyopia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 5, 1 and 2 respectively.
Presbyopia (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Presbyopia (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Presbyopia (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Presbyopia (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Presbyopia (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Presbyopia (Ophthalmology)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Presbyopia (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Presbyopia (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Presbyopia - Overview
Presbyopia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Presbyopia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Presbyopia - Companies Involved in Therapeutics Development
Acucela Inc
Allergan Plc
Johnson & Johnson
Novartis AG
Presbyopia - Drug Profiles
(aceclidine + tropicamide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diclofenac sodium + pilocarpine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(oxymetazoline hydrochloride + pilocarpine hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EV-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanosterol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
oxymetazoline hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Beta-L Crystallin for Cataract and Presbyopia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VP-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Presbyopia - Product Development Milestones
Featured News & Press Releases
May 05, 2016: Encore Vision Announces Successful Phase I-II Study of Topical EV06 for the Treatment of Presbyopia
May 02, 2016: Encore Vision Announces Positive Results from the Phase I-II Study of Topical EV06 for the Treatment of Presbyopia
Jan 25, 2016: Encore Vision Announces Completion of Target Enrollment
Oct 05, 2015: Encore Vision Announces First Subject Enrolled in Study of Topical Treatment for Presbyopia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List Of Tables
Number of Products under Development for Presbyopia, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Presbyopia - Pipeline by Acucela Inc, H2 2017
Presbyopia - Pipeline by Allergan Plc, H2 2017
Presbyopia - Pipeline by Johnson & Johnson, H2 2017
Presbyopia - Pipeline by Novartis AG, H2 2017
List Of Figures
Number of Products under Development for Presbyopia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Presbyopia - Pipeline Insight, 2021
DelveInsights, Presbyopia - Pipeline Insight, 2021, report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Presbyopia pipeline landscape. It covers the pipeline drug profiles, including clinical and
USD 1500 View ReportPresbyopia - Pipeline Review, H1 2020
Presbyopia - Pipeline Review, H1 2020 latest Pharmaceutical and Healthcare disease pipeline guide Presbyopia - Pipeline Review, H1 2020, provides an overview of the Presbyopia (Ophthalmology) pipeline landscape.Presbyopia is an
USD 2000 View ReportNatural Killer Cell Therapies - Pipeline Insight, 2021
DelveInsights, Natural Killer Cell Therapies - Pipeline Insight, 2021, report provides comprehensive insights about 100+ companies and 140+ pipeline drugs in Natural Killer Cell Therapies pipeline landscape. It covers the
USD 3000 View ReportBinge-eating disorder - Pipeline Insight, 2021
DelveInsights, Binge-eating disorder - Pipeline Insight, 2021, report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Binge-eating disorder pipeline landscape. It covers the pipeline drug profiles, including
USD 1500 View ReportFill The Form For Sample Request